NFE2L2 and neoplasm: Different mechanisms can lead to aberrant sustained activation of NRF2 signalling in tumour cells, including somatic mutations in NFE2L2 or KEAP1, exon 2 skipping in NFE2L2, KEAP1 downregulation due to promoter hypermethylation, and transcriptional activation of NFE2L2 gene [17].